A RGININE VASOPRESSIN (AVP), a nonapeptide originally described for its role in the regulation of renal fluid balance, is a potent neuromodulator. AVP-expressing neurons are found in a number of brain regions including the bed nucleus of the stria terminalis (BST), medial amygdala (MeA), paraventricular nucleus (PVN), supraoptic nucleus (SON), and suprachiasmatic nucleus (SCN), all of which participate in the regulation of centrally mediated behaviors (1-3), circadian rhythms (4, 5) , and the stress response (6 -8) as well as fluid balance. AVP expression in the BST and MeA is gonadal steroid dependent because gonadectomy of adult male animals abolishes AVP immunoreactivity and testosterone (T) replacement fully restores expression (9, 10) .
In the brain, T can be considered a multifunctional precursor hormone. Upon entry into a target cell, T may be converted to 17␤-estradiol (E2) or 5␣-dihydrotestosterone (DHT), depending on the presence of the enzymes, aromatase or 5␣-reductase, respectively. T may also bind and activate androgen receptors (AR) directly. Interestingly, both E2 and DHT are required to restore AVP immunoreactivity to the level seen in intact male rats, with E2 restoring approximately 90% and DHT restoring about 10% of AVP-expressing cells (11) . These data have been interpreted to indicate that estrogen receptor (ER) and AR pathways independently mediate AVP expression, yet both are required for full expression. However, the molecular mechanism for the androgenic regulation of AVP has not been demonstrated.
Classically, androgens activate transcription through AR. AR belong to the larger superfamily of nuclear receptors and are classified as class I ligand-activated transcription factors (12) . AR are found in AVP-expressing cells in the BST and MeA (13, 14) . DHT binds with higher affinity to AR than does T, and both activate transcription by directing the AR to bind to an androgen response element located within the promoter region of androgen-responsive genes.
Alternatively, DHT can be converted to 5␣-androstane-3␤,17␤-diol (3␤Adiol), or its stereoisomer 3␣Adiol, by a variety of steroid-metabolizing enzymes, including 17␤-hydroxysteroid dehydrogenase (17␤HSD), 3␣-hydroxysteroid oxidoreductase (3␣HSD), and 3␤-hydroxysteroid oxidoreductase (3␤HSD) (15, 16) . Although 3␣Adiol maintains bidirectional catalysis with DHT, the conversion to 3␤Adiol is irreversible. Notably, recent reports have shown that despite the androgenic origin of 3␤Adiol, it preferentially binds and activates ER␤ and has a low binding affinity for AR (17) . Furthermore, we have previously established that 3␤Adiol's ability to activate transcription through ER␤ is mediated by an estrogen response element (ERE) (18) . Together, these data raise the possibility that DHT increases AVP expression indirectly, by metabolism to a compound that acts through an ER-and not AR-mediated pathway.
There are two subtypes of ER, termed ER␣ and ER␤, which are encoded by distinct genes but have highly homologous DNA-binding domains (97%) (19) . Furthermore, the binding affinities of ER␣ and ER␤ for E2 are relatively similar despite only 57% homology in their ligand-binding domains (19, 20) . At least three splice variants of ER␤ (also called ER␤1) have been identified in rodents since its first detection in 1996. These include variants lacking the third exon (␦3), lacking the fourth exon (␦4), or with an insert between exons 5 and 6 (␤2). Combinations of these three result in a number of different variant mRNAs (21) (22) (23) (24) . Although a functional significance for these variant forms of ER␤ has yet to be elucidated, they are found in numerous tissues including many brain areas (22, 23, 25) .
The present study addressed two central hypotheses: 1) that androgens directly modulate AVP promoter activity and 2) the effect is mediated by an ER or AR pathway. To that end, we overexpressed AR, ER␤, and ER␤ splice variants in a neuronal cell line and measured AVP promoter activity using a firefly luciferase reporter assay. Our results demonstrate that DHT and its metabolite 3␤Adiol stimulate AVP promoter activity through ER␤ in a neuronal cell line.
Materials and Methods

Transient transfections
Cell culture. The human neuroblastoma-derived cell line SK-N-SH (American Type Culture Collection, Manassas, VA), was used for all transient transfections. Cells were maintained in MEM with Earle's salts, containing 4.5% glucose and l-glutamine (Invitrogen Inc., Carlsbad, CA) supplemented with 1ϫ nonessential amino acids and 10% fetal bovine serum (Gemini Bioproducts, Woodland, CA). Cells were grown to 70% confluency, and all transient transfection experiments were performed within 10 passages.
Expression vectors. Plasmid expression vectors for ER included a pcDNA 3.0 vector (Invitrogen, Carlsbad, CA) containing a cDNA insert coding for rat ER␤1, rat ER␤1␦3, and rat ER␤2 (generously provided by Dr. Tom Brown, Pfizer Corp, Cambridge, MA). The GRIP-1 (NR box) expression vector consisted of the amino acid sequence 629 -760 of the glucocorticoid receptor interacting protein-1 (GRIP1) subcloned into the pM vector (generously provided by Dr. Donald P. McDonnell and Julie M. Hall, Duke University, Durham, NC). The AR expression vector consisted of a pCMV vector containing a cDNA insert coding for full-length rat AR (generously provided by Drs. Cynthia L. Jordan and Douglas A. Monks, Michigan State University, Lansing, MI). Upon receipt, the fulllength AR was digested from the pCMV vector at the BglII and BamHI restriction sites and subsequently subcloned into the pcDNA 3.1 expression vector (Invitrogen). The pcDNA/AR expression vector was validated by transient transfection into SK-N-SH cells followed by 15 h of 10 nm DHT treatment. AR protein was detected using immunocytochemistry and was determined to be functional if DHT induced a translocation of AR immunoreactivity from the cell cytoplasm to the nucleus (see Fig. 1 ).
Reporter constructs. The full-length rat AVP promoter (5446 bp) was subcloned into the promoterless luciferase vector (pGL2 basic; generously provided by Drs. Daniel M. Dorsa and Robert A. Shapiro, OR Health & Science University, Portland, OR). Truncations were made by restriction enzyme digestion upstream from the transcription start site at position Ϫ1370 (AVP1.3), Ϫ740 (AVP740), and Ϫ306 (AVP306) and subsequently subcloned into the pGL2 basic promoterless luciferase vector. The pJ3 reporter construct (generously provided by Dr. Rosalie Uht, University of Virginia, Charlottesville, VA), expressing ␤-galactosidase under the control the sv40 promoter, was used as an internal control for calculating plasmid transfection efficiency.
Transfections. Cells were plated at a density of 0.5 ϫ 10 5 cells per well in 24-well plates for 48 h before transfection to achieve a final confluency of 70 -80%. All constructs were transfected in triplicate wells within each assay, and each transfection assay was repeated a minimum of six times. Each experiment was performed using a minimum of three different preparations for each plasmid. Transfections were carried out using a lipid-mediated transfection reagent (Fugene6; Roche Molecular Biomedical, Indianapolis, IN) according to the manufacturer's instructions. Cells were incubated with transfection media complex overnight followed by replacement with MEM containing 10% dextran-charcoal-stripped fetal bovine serum (Hyclone Laboratories, Logan, UT) to ensure steroid-free culture conditions. Twenty-four hours after transfection, cells were incubated with media containing hormone treatments for 15 h and then lysed for luciferase analysis. All treatments were performed in MEM containing 10% dextran-charcoal-stripped fetal bovine serum to ensure depletion of all endogenous steroid hormones. In addition, each transfection experiment was performed a minimum of three times with phenol red-free media, and no differences were observed from the transfections performed with media containing phenol red. Luciferase activity was measured using 20 l cell lysate added to 100 l luciferin substrate (Promega Corp., Madison, WI). ␤-Galactosidase activity was measured using 40 l cell lysate added to 200 l galacton substrate (Tropix-GalactoLight kit; Applied Biosystems, Foster City, CA) accord- ing to the manufacturer's instructions. Relative light units were measured using a 20/20 TD luminometer (Turner Designs, Sunnyvale, CA).
Hormone treatments. The following compounds were diluted in 95% ethanol (EtOH) (vehicle control) and used at a final concentration of 100 nm in 0.001% EtOH: 3␤Adiol, E2, and DHT (Steraloids, Newport, RI). Each compound was added to MEM with Earle's salts supplemented with 10% dextran-charcoal-stripped fetal bovine serum (Hyclone Laboratories, Logan, UT).
Site-directed mutagenesis. The putative ERE located at position Ϫ995/ Ϫ984 of the AVP promoter was deleted using the QuikChange II XL kit according to manufacturer's instructions (Stratagene, La Jolla, CA). Briefly, the primer sequence 5Ј-GCTATGTAGTAAAGCCTGGACTA-AACGACTGC-3Ј was designed to target the desired region of the AVP promoter. A standard PCR was performed on a thermal cycler using the AVP1.3-luciferase reporter construct as a template. After the reaction, the parent plasmid was digested using the DpnI restriction enzyme and the daughter plasmid, containing the desired mutation, was transformed into XL-10 Ultragold competent cells and amplified. The presence of the site-directed mutation was confirmed by DNA sequencing (Retrogen Inc., San Diego, CA).
RT-PCR
RNA isolation. Total RNA was isolated from SK-N-SH cells using the guanidinium thiocyanate method (26 PCR. PCR was performed using FastStart DNA Master SYBR Green I kit according to manufacturer's instructions (Roche). Optimal MgCl 2 concentration was experimentally determined for each set of primers. Five picomolar of forward and reverse primer was added per reaction. Master mix containing MgCl 2 , SYBR Green, and primer pairs were aliquotted into capillary tubes (Roche) followed by the addition of 1/20th of the RT reaction, except control, which received DNA-free water of the same volume. In a Roche Light Cycler, capillary tubes were heated to 95 C for 6 min, then a repeated cycle specific to each primer (see below) with florescence detection at the end of each 72 C step, and then melted with continuous florescence detection to 95 C. PCR products were resolved on a 2% agarose gel and compared with a DNA ladder of known size (Fisher Scientific, Pittsburgh, PA; Exactgene 50-bp ladder) to confirm product size, and to verify specificity, the products were subjected to a thermal melting curve analysis to determine whether the melting temperature of the product was consistent with the calculated theoretical melting temperature based on sequence.
The following primer sequences targeting the human sequence for the gene indicated and specific repeated cycle conditions are as follows: 17␤HSD forward, 5Ј-CCGGGAGCGTGGGAGGATTGAT 3Ј, and reverse, 5Ј-TCGGTGGTGAAGTAGCGCAGGG-3Ј (95 C for 2 sec, 68 C for 5 sec, and 72 C for 15 sec); 3␤HSD forward, 5ЈTCATCCACACCGCCT-GTATCAT-3Ј, and reverse, 5Ј-TTTCAGATTCCACCCGTTAGCC-3Ј (95 C for 2 sec, 64 C for 5 sec, and 72 C for 12 sec); AR forward, 5Ј-GACAACAACCAGCCCGACTCCT-3Ј, and reverse, 5Ј-GCTGTA-CATCCGGGACTTGTGC 3Ј (95 C for 2 sec, 67 C for 5 sec, and 72 C for 12 sec); and ER-␤1 forward, 5Ј-CCTGACCAAGTTGGCCGACAAG-3Ј, and reverse, 5Ј-CTGGGAGGAGATGCCGCTCTT-3Ј (95 C for 2 sec, 66 C for 5 sec, and 72 C for 19 sec).
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde in 0.1 m phosphate buffer for 10 min. The cells were 1) rinsed with 0.1 m PBS, 2) blocked and permeabilized with 0.1% BSA/0.3% Triton X/PBS for 1 h, 3) incubated overnight at 4 C with the polyclonal rabbit androgen receptor antibody PG-21 at 1:1000 dilution (provided by Dr. G. Prins), 4) rinsed with PBS, 5) incubated with biotinylated goat antirabbit (Vector Laboratories, Burlingame, CA), 6) rinsed with PBS, 7) incubated with biotin-coupled horseradish peroxidase and avidin (ABC Elite, Vector) at 1:800 dilution, 8) rinsed with 0.05 m Tris-buffered-saline, and 9) finally reacted with 0.05% diaminobenzidine/0.25% nickel ammonium sulfate/0.01% H 2 O 2 /Tris-buffered saline for 10 min.
Statistics
Data were analyzed by two-way ANOVA (hormone treatment ϫ plasmid concentration) followed by Tukey's honestly significant difference test. Differences were considered significant when P Ͻ 0.05. All transfection data are represented as percent change compared with vehicle-treated, empty vector controls.
Results
Characterization of AR expression in the SK-N-SH neuronal cell line
For these studies, we used the neuroblastoma-derived cell line SK-N-SH as a model system. Cells were initially tested for the presence of endogenous AR. Real-time RT-PCR indicated an absence of AR mRNA in this cell line (Fig. 1A) . Next, SK-N-SH cells were transiently transfected with the AR expression vector to determine whether the exogenously transfected AR plasmid construct produced functional AR protein. These results showed that cells transfected with an empty vector control (pcDNA3.1) showed no AR immunoreactivity irrespective of hormone treatment (Fig. 1B , panels I and II). In contrast, after transient transfection with an AR-containing plasmid, AR immunoreactivity was detected and was primarily localized to the cytoplasm of vehicletreated cells (Fig. 1B, panel III ; see inset). After treatment with 10 nm DHT, there was a hormone-dependent translocation of AR immunoreactivity to the nucleus (Fig. 1B, panel IV, see  inset) . Together, these results validated the efficacy of our transfection system and the functionality of our AR expression vector.
Effects of DHT on AR-mediated AVP promoter-luciferase activity
To determine whether androgens directly modulate AVP promoter activity through an AR-mediated mechanism, we cotransfected SK-N-SH cells with an expression vector containing rat AR and with a luciferase reporter construct containing the full-length (5.5 kb) rat AVP promoter (Fig. 2) . Cells were then treated with either vehicle or DHT for 15 h. Overexpression of AR, at plasmid concentrations of 0.5 and 1.0 g, significantly reduced full-length (5.5 kb) AVP promoter-luciferase activity in cells treated with vehicle alone (Fig. 3A) . However, these same concentrations of plasmid AR also significantly reduced luciferase activity in cells cotransfected with AR and the promoterless luciferase reporter construct (data not shown). There was no significant difference in the AR-induced reduction of luciferase activity between the promoterless and the AVP promoter-containing luciferase reporter constructs, suggesting that overexpression of AR in these cells induced a generalized squelching of transcription that was not specific to the AVP promoter. Similar effects were observed when the AVP promoter was truncated at 1.3 kb (Figs. 2 and 3B) .
Treatment with 10 nm DHT significantly reduced fulllength AVP (5.5 kb) promoter-luciferase activity in cells transfected with 0.1 g plasmid AR (Fig. 3A) . This liganddependent effect was abolished with the truncated AVP promoter (1.3 kb), suggesting that the site of AR-mediated inhibition by DHT lies upstream of the 1.3-kb region of the AVP promoter (Fig. 3B) .
Characterization of androgen metabolic enzymes in the SK-N-SH neuronal cell line
The nonaromatizable androgen DHT can be further metabolized intracellularly to 3␤Adiol and its stereoisomer 3␣Adiol (Fig. 4) . Because 3␤Adiol has been shown to have a high affinity for binding ER␤, we next determined whether the SK-N-SH neuronal cell line endogenously expressed the enzymes necessary to convert DHT to 3␤Adiol. The primary enzymes involved in the conversion process have been identified as 3␤HSD and 17␤HSD (15, 16) . Results of amplification by real-time RT-PCR demonstrated the presence of both enzyme mRNAs in SK-N-SH cells (Fig. 5, A and B) . Gel electrophoresis of the PCR product showed three distinct bands for 17␤HSD mRNA that correspond to the three different isoforms of 17␤HSD (Fig. 5B) . Our results also demonstrated that ER␤1 was endogenously expressed in this cell line (Fig. 5C ). The prostate tumor-derived LNCaP cell line was used as a positive control for these experiments.
Ligand-dependent and ligand-independent effects on fulllength (5.5 kb) AVP promoter activity mediated by ER␤ splice variants
To determine whether DHT, or its metabolite 3␤Adiol, regulates AVP promoter activity through an ER␤-mediated mechanism, we cotransfected SK-N-SH cells with the fulllength (5.5 kb) AVP promoter-luciferase reporter construct and an expression vector containing either ER␤1, ER␤1␦3, or ER␤2 (Fig. 6) . Overexpression of ER␤1 caused a robust ligand-independent increase in AVP promoter activity that is consistent with previous results (Fig. 6 ). In addition, treat- ment with DHT and 3␤Adiol, but not E2, significantly augmented the ligand-independent effect. The splice variant ER␤1␦3 is lacking exon 3, the coding sequence for the second zinc finger of the DNA-binding domain, resulting in an inability to bind DNA efficiently (23) . Cotransfection with ER␤1␦3 had no effect on AVP promoter activity even in the presence of a ligand (Fig. 6) , suggesting that DNA binding is required for ER␤-mediated AVP promoter activity.
The splice variant ER␤2 contains an 18-amino-acid sequence in the ligand-binding domain that is not present in the other ER␤ splice variants. Similar to ER␤1, cotransfection with ER␤2 significantly increased AVP promoter activity in a ligand-independent fashion, although the magnitude of the increased activity was significantly less (ϳ50%) than that of ER␤1 (P Ͻ 0.05). However, in contrast to results using ER␤1, treatment of ER␤2-expressing cells with E2 and 3␤Adiol, but not DHT, significantly increased AVP promoter activity (Fig. 6) .
Determining a site of action for ER␤-induced AVP promoter activity using truncated AVP promoter-luciferase reporter constructs
Previous studies suggested that ER␤1 increased AVP promoter activity in a ligand-independent fashion and identified the putative site of action as located between Ϫ4.0 and Ϫ1.1 kb upstream from the transcriptional start site (27) . To more precisely define a location on the proximal AVP promoter that is required for the ligand-independent and -dependent actions of ER␤1 and ER␤2, we deleted regions of the promoter from the 5Ј end at the following locations upstream from the transcriptional start site: Ϫ1370 (AVP1.3), Ϫ740 (AVP740), and Ϫ306 (AVP306). Successive deletion of the 5Ј end of the AVP promoter significantly increased basal activity for the AVP740 and AVP306 constructs (Fig. 7) . The mean increase in basal activity was 195 Ϯ 27 and 179 Ϯ 22% for AVP740 and AVP306, respectively. There was no significant effect of the deletion on the basal activity of the AVP1.3 promoter construct (Fig. 7) .
AVP1.3 promoter construct.
Cotransfection of AVP1.3 with ER␤1 and ER␤2 resulted in similar responses to those seen with the full-length promoter. Overexpression of ER␤1 induced a significant increase in AVP1.3 promoter activity in the absence of hormone treatment (Fig. 8A) . However, contrary to results using the full-length promoter, hormone treatments did not further augment the ligand-independent increase in AVP1.3 promoter activity induced by ER␤1 (Fig.  8A) . Cotransfection of ER␤2 with the AVP1.3 promoter produced the same response seen with the full-length (5.5 kb) AVP promoter (Figs. 6 and 8A) . A significant ligand-independent increase was observed, and the effect was further enhanced with E2 and 3␤Adiol, but not DHT, treatment (Fig.  8A) .
AVP740 promoter construct.
Cotransfection with ER␤1 increased ligand-independent activity of the AVP740 promoter; however, the effect was greatly reduced from that of the full-length (5.5 kb) promoter (330.9 and 1169.7%, respectively; Figs. 7 and 9B). Hormone treatments had no effect on AVP740 promoter activity mediated by ER␤1. The pattern of AVP740 promoter activity when cotransfected with ER␤2 was similar to the AVP1.3 and AVP5.5 constructs. Overexpression of ER␤2 induced a significant ligand-independent increase in AVP740 promoter activity, although, like ER-␤1, the effect was not as robust as seen with the full-length construct (228.3 and 619.5%, respectively; Figs. 6 and 8B). Treatment with DHT and 3␤Adiol significantly increased AVP740 promoter activity above the ligand-independent levels to a similar degree observed with the full-length construct (Fig. 8B) .
AVP306 promoter construct. Deletion of the AVP promoter at position Ϫ306 resulted in greatly reduced ligand-independent effects of ER␤1 and ER␤2. Unlike what was observed with the previous AVP promoter constructs, both ER␤1 and ER␤2 increased AVP306 promoter activity equivalently (Fig.  8C) . Furthermore, the hormone-dependent increase observed with ER␤2 was completely abolished with the AVP306 promoter (Fig. 8C) . 
Effects of putative ERE deletion on ER␤-induced ligandindependent AVP promoter activity
Two functional consensus ERE sequences have been identified in the most distal 1-kb region of the AVP promoter (27) . These regions were shown to be important for some of the ligand-dependent regulation of the AVP promoter mediated by ER␣. Here, we have identified a putative ERE in the proximal region of the promoter beginning at position Ϫ984 (Fig. 2) . This experiment was designed to determine whether the proximal ERE is important for the ligand-independent action of ER␤1 and ER␤2. We used site-directed mutagenesis to destroy the putative ERE in the AVP1.3 promoter construct (AVP1.3␦ERE; Fig. 2 ). This construct was selected because it lacked the distal EREs, yet it functionally resembled the activity of the full-length promoter when cotransfected with ER␤1 and ER␤2.
Similar to results shown with the AVP1.3 promoter construct, cotransfection of ER␤1 with AVP1.3(␦ERE) induced a robust ligand-independent increase in promoter activity (Fig. 9) . However, deletion of the proximal ERE resulted in a significant ligand-dependent increase in promoter activity mediated by ER␤1. Treatment with DHT and 3␤Adiol, but not E2, significantly augmented the ligand-independent increase in promoter activity (Figs. 8A and 9). Cotransfection with AVP1.3(␦ERE) and ER␤2 yielded similar results as those observed with the AVP1.3 promoter construct (Figs. 8A and  9) . Thus, deletion of the proximal ERE had no significant effect on ligand-independent promoter activity mediated by ER␤2 (Fig. 9) . However, treatment with 3␤Adiol was significantly more effective at augmenting the ligand-independent effect than E2 (Fig. 9 ). This result is contrary to what was observed with the AVP5.5, AVP1.3, and AVP740 promoters. With those promoter constructs, E2 and 3␤Adiol equally increased promoter activity above levels achieved with the ligand-independent effect (P Ͻ 0.05; Figs. 6 and 8, A and B) .
The coregulatory protein GRIP1 is required for 3␤Adiol-induced stimulation of AVP promoter activity mediated by ER␤1
The recruitment of coregulatory proteins is an important component of ER signaling pathways (28) . To determine whether the coactivator GRIP1 is required for ER␤1-induced AVP promoter activity, the full-length (5.5 kb) AVP promoter-luciferase reporter construct was cotransfected with an expression vector containing ER␤1 and an expression vector containing the NR-box sequence (amino acids 629 -760) from GRIP1 (GRIP-NRbox). The GRIP-NRbox expression vector serves as a dominant negative by preventing endogenous GRIP1 protein from interacting with ER␤1 (29) . Overexpression of ER␤1 induced a robust ligand-independent increase in AVP promoter activity that was unaffected by the GRIPNRbox construct (Fig. 10) . However, although treatment with 3␤Adiol significantly augmented the ligand-independent effect in control cells, it had no effect in cells transfected with GRIP-NRbox (Fig. 10) .
Discussion
Together, these experiments revealed important information that furthers our understanding of how gonadal steroid hormones regulate AVP promoter activity. First, we have demonstrated a potential molecular mechanism for the androgenic regulation of AVP expression in some brain areas.
Our results show that DHT acts through AR to inhibit AVP promoter activity but does not work through AR to increase AVP promoter activity, whereas DHT and its metabolite 3␤Adiol can stimulate AVP promoter activity through ER␤1 and ER␤2. Second, we have provided evidence that ER␤ splice variants might play an important role in differentially modulating AVP expression in neuronal cells. ER␤1 and -␤2 induced a strong constitutive activation of the AVP promoter in addition to their ligand-dependent effects, suggesting that up-regulation of these receptors in AVP-containing cells is sufficient to alter AVP expression profiles in the brain. Third, ER␤1 and ER␤2 have differing ligand-dependent effects and act at different regions of the AVP promoter to exert their ligand-dependent effects, thereby providing an additional level of complexity for gonadal steroid hormone regulation of AVP. Finally, our results confirmed that the nuclear receptor coactivator protein GRIP is required for 3␤Adiol to induce AVP promoter activity when mediated by ER␤1. This raises the possibility that ER␤1 and ER␤2 can differentially regulate AVP expression through the selective recruitment of coregulatory proteins. Several lines of evidence suggested that androgens exert a stimulatory effect on AVP expression in specific brain regions (11, 30, 31) . In adult male rats, castration abolished and T treatment restored AVP expression in the BST and MeA (9) . Furthermore, treatment with DHT significantly increased AVP expression in the SON of hyperosmotic rats (30) and in the medial parvocellular neurons of the PVN, an important neural component regulating the hormonal response to a stressor (31) . Because DHT has been thought to be a nonaromatizable metabolite of T that acts exclusively through AR, these data provided strong evidence that AR played a critical role in mediating central AVP expression. However, our results argue against this hypothesis. Instead, we have shown that DHT inhibited AVP promoter activity when mediated by low levels of AR. 3␤Adiol, a metabolite of DHT, is a functional ligand for ER␤1 and ER␤2 in neuronal cells (18) , raising the possibility that DHT-induced AVP expression in the brain is mediated by ER␤. Previously, we demonstrated that in vivo, 3␤Adiol activated ER␤-expressing neurons in the PVN of adult rats (32) . Here, we show that 3␤Adiol significantly potentiated the ligand-independent effect of ER␤1 and ER␤2 on AVP promoter activity in vitro. DHT has a very low binding affinity for ER (19) ; therefore, it is reasonable to assume that the stimulatory effects of DHT on AVP promoter activity mediated by ER␤1 were accomplished through its intracellular conversion to 3␤Adiol. Moreover, DHT cannot be converted to T, ruling out the possibility that the observed DHT effect is through back conversion to T and then E2. Also, we have confirmed that the enzymes necessary to convert DHT to 3␤Adiol are expressed in the SK-N-SH cell line. The failure of DHT to stimulate ER␤2-mediated AVP promoter activity might be due to the considerably lower binding affinity 3␤Adiol has for ER␤2 than ER␤1 (K i ϭ 58.1 and 1.7 nm, respectively) (18) .
Over the last decade several splice variants have been identified for both ER␣ and ER␤ mRNAs (22, 24, (33) (34) (35) . In humans, there are five isoforms of ER␤ (ER␤1-ER␤5), all of which diverge at similar positions in helix 10 (36). In the rat brain, four splice variants of ER␤1 are expressed: ER␤1␦3, E-␤1␦4, ER␤2, and ER␤2␦3 (24, 25) . Although these splice variants have been identified in some regions of the rat brain that express AVP (SON, PVN, and MeA), it remains to be determined which splice variants are coexpressed with AVP in individual cells. These variants arise from the alternative splicing of heterogeneous nuclear RNA and thus have distinct structural and functional characteristics. For example, ER␤2 has an 18-amino-acid insert in the ligand-binding domain that is absent from ER␤1, thus allowing for differential ligand selectivity. In humans, the isoform termed ER␤2 (also called ER␤cx) is not homologous to the rat ER␤2 but rather contains a novel carboxy terminal end. To date, a human equivalent of the rat ER␤2 (i.e. one containing an 18-aminoacid insert in the ligand-binding domain) has not been identified. The ␦3 variants are missing exon 3, which codes for the second zinc finger of the DNA-binding domain (23) , whereas the ␦4 variant is missing exon 4, which codes for the portion of the hinge region that contains the nuclear localization signal (24) . In this study, we used the different splice variants of ER␤ to better understand the dynamics of ER␤-mediated promoter activity. For instance, our results using ER␤1␦3 suggest that direct DNA binding of the receptor is required for both the ligand-independent and ligand-dependent effects of ER␤1 on AVP promoter activity.
Perhaps the most intriguing finding in this study is the observation that ER␤2 activated AVP promoter activity differently from ER␤1. Previous studies examining the function of ER␤2 have indicated that it activates transcription similar to that of ER␤1 (20, 21) . Here we showed that unlike ER␤1, both E2 and 3␤Adiol significantly augmented the ligandindependent increase in AVP promoter when mediated by ER␤2. Furthermore, the site of action for 3␤Adiol/ER␤2-induced activation of the AVP promoter lies at Ϫ306 to Ϫ740 bp upstream from the transcription start site, whereas the functional site of 3␤Adiol/ER␤1-mediated AVP promoter activity lies more than 1.3 kb upstream. These data demonstrate that the regulation of the AVP promoter varies depending on which ER variant is present in a given cell. However, determining precisely which splice variants are coexpressed with AVP in differing brain areas is severely limited by current techniques. Given that the number of newly described nuclear receptor splice variants has grown at a rapid pace and is constantly changing, they represent potential alternative mechanisms to unlock the complexities of gonadal steroid hormone-regulated gene transcription.
Using the splice variant ER␤1␦3, we have shown that DNA binding is required for both the ligand-independent and ligand-dependent actions of ER␤1 and ER␤2. However, we found only one candidate sequence for a putative ERE in the proximal 1.3-kb region of the AVP promoter. This proximal ERE consists of two consecutive canonical half sites at position Ϫ995/Ϫ984 upstream from the transcription start site. We used site-directed mutagenesis to abolish this region to determine whether it was required for ER␤-mediated AVP promoter activity. Our results showed that neither the ligand-independent nor ligand-dependent effects of ER␤1 and -␤2 on AVP promoter activity was altered by destruction of the putative ERE. Moreover, in this region, there is no evidence of other known sites where steroid receptors can interact, such as an activator protein-1 or Sp-1 site. The absence of a canonical ERE at the ER␤ site of action in the AVP promoter raises the possibility that ER␤1 and ER␤2 can bind and activate novel DNA sequences. In support of this hypothesis, we have previously shown that ER␤1 significantly increased GnRH promoter activity in a ligand-independent fashion and that the site of action lacked a known hormone response element (37) .
The constitutive activation of gene promoters by ER␤1 and its splice variants demonstrate a unique property of ER␤ that is not shared by its counterpart, the originally described estrogen receptor ER␣. Of the gene promoters investigated to date, all are regulated in a ligand-independent fashion by ER␤, including CRH (38), GnRH (37) , and as shown herein and by others, AVP (27) . Collectively, these data suggest that ER␣ and ER␤ serve different physiological functions and potentially regulate gene networks through very different intracellular mechanisms. Consistent with our findings, Shapiro and colleagues (27) showed a concentration-dependent, ER␤-induced increase in AVP promoter activity that occurred in the absence of hormone treatment. In comparison, we observed significant ligand-independent increases in AVP promoter activity at concentrations of ER␤1 that were one tenth of that used by Shapiro and colleagues (27) to see an effect and one half of that which elicited no effect (0.5 g/well; data not shown). Moreover, Shapiro et al. (27) found that the effect of E2 treatment on ER␤-mediated AVP promoter activity was dependent on the concentration of ER␤. E2 increased AVP promoter activity at low concentrations of ER␤, whereas it failed to increase AVP promoter activity at higher concentrations. However, in our hands, E2 failed to further augment AVP promoter activity above the ligandindependent effect at concentrations of ER␤ similar to those tested by Shapiro et al. (27) . One possible explanation for these discrepancies is that the ER␤ construct used in these studies was 45 amino acids longer than that used by Shapiro et al. (27) . Shortly after the originally reported sequence of 485 amino acids for ER␤ (19) , it was discovered that the true transcription start site reflected a length of 530 amino acids (39) . The higher basal activity of ER␤1 observed in our study might be explained by these additional 45 amino acids.
Nuclear receptor signaling is propagated by the recruitment of various coregulatory proteins. Coregulators are integral components of the transcriptional machinery participating in everything from chromatin remodeling to the stabilization of RNA polymerases (40, 41) . The nuclear receptor coactivator protein GRIP1 (also called SRC-2, TIF2, and NCoA-2) has been shown to be an important regulator of ER signaling (42, 43) . Moreover, ER␤ differentially recruits coactivators in response to different ligands (28) . In this study, we used a dominant-negative GRIP1 expression vector (29) to begin to elucidate some of the downstream molecular participants involved in ER␤-mediated regulation of the AVP promoter. The expression vector we used contained the NR-box sequence (amino acids 629 -760) from GRIP1 subcloned into the pM plasmid vector. The NR-box sequence will bind to the LXXLL motif of the transfected ER␤1 construct thereby preventing any endogenous GRIP1 protein from interacting with ER␤1. Using this strategy, we found that GRIP1 was not required for the ligand-independent activation of AVP promoter activity by ER␤1. By contrast, by squelching endogenous GRIP1 activity we completely abolished the 3␤Adiol-induced activation of the AVP promoter, suggesting that the GRIP1 (NR-box) interfered with the function of the endogenously expressed GRIP1 protein. These results indicate that GRIP1 is an important player in ER␤1's ligand-dependent regulation of AVP by 3␤Adiol and also suggest that the downstream pathways regulating liganddependent and ligand-independent activation of ER␤1 are distinct.
The role of central AVP release has been at the forefront of research examining the intricacies of social and intimate behaviors. For males in particular, activation of central AVP receptors has been shown to influence the pair-bonding preferences and paternal care behaviors in voles (44, 45) . AVP also mediates scent-marking behaviors in hamsters (46) . Furthermore, AVP expression in brain regions that mediate these male-typical behaviors has been shown to be androgen dependent (9) . The data presented herein demonstrate that ER␤ is a likely candidate for mediating the DHT effects on AVP expression, suggesting that ER␤ might be required for the proper execution of male social behaviors. This is particularly significant given the differential distribution of ER␣, ER␤, and its splice variants in specific brain nuclei. Moreover, we have shown specific regions of the AVP promoter that are important for ER␤ regulation despite the lack of any known hormone response elements. These data raise important new questions about novel DNA-binding sites and/or interacting proteins and their significance for ER␤-mediated gene transcription. Finally, these data underscore the importance of complex promoters and the necessity for multiple levels of regulation. In the case of AVP, it allows for differential regulation of gene expression in discrete neuronal populations, under varying homeostatic conditions (i.e. hypernatremia, circulating hormone levels, etc.), and with varying expression of ER splice variants within a given cell.
